Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Acadia Pharmaceuticals (ACAD)

Acadia Pharmaceuticals R&D chief Elizabeth Thompson to retire; search for successor begins

Neutral Impact 4 of 5 leadership Written later

Acadia Pharmaceuticals said its Head of Research and Development, Elizabeth H.Z. Thompson, Ph.D., plans to retire for personal reasons. She will stay in the role until a successor is appointed and then serve as a consultant through at least the end of 2026, including through the planned Phase 2 readout of remlifanserin in Alzheimer's disease psychosis. The filing matters to shareholders because it changes leadership of the company's research program during a key clinical period.

Key points

  • Dr. Thompson informed the company of her planned retirement on April 27, 2026, and the company announced it on April 30, 2026.
  • She will remain Head of Research and Development until a successor is appointed, then serve as a consultant through at least the end of 2026.
  • The company has initiated a search for a replacement; no successor is named in the filing.
  • The Phase 2 remlifanserin study in Alzheimer's disease psychosis continues to recruit and remains blinded, and the company does not yet know outcomes.

The filing

CompanyAcadia Pharmaceuticals (ACAD)
Form8-K, current report
Filed with the SECApr 30, 2026, 5:34 PM ET
Accession number0001193125-26-197957

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.